(LLY) Eli Lilly - Ratings and Ratios

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader specializing in the discovery, development, and distribution of innovative medicines. The company operates across major markets, including the United States, Europe, China, Japan, and other international regions. Its diabetes portfolio includes a range of insulin products such as Basaglar, Humalog, and Humulin, as well as newer therapies like Jardiance, Mounjaro, and Trulicity for type 2 diabetes. The company also offers Zepbound for obesity management. In oncology, key products include Alimta, Cyramza, and Verzenio, addressing various cancers. Lilly’s immunology and neuroscience divisions provide treatments for conditions like rheumatoid arthritis, psoriasis, and migraines through drugs such as Olumiant, Taltz, and Emgality. The company collaborates with major industry players, including Incyte, Boehringer Ingelheim, and Roche, to advance therapeutic innovations. Founded in 1876, Lilly is headquartered in Indianapolis, Indiana, and maintains a strong commitment to research and patient care.

Lilly’s strategic focus on next-generation therapies, including its groundbreaking GLP-1 receptor agonist Mounjaro, has positioned it as a leader in diabetes and obesity treatment. The company’s oncology pipeline, supported by collaborations with Biologics, Inc., and AbCellera Biologics, aims to deliver targeted cancer therapies. Lilly’s immunology portfolio continues to expand, with Ebglyss recently approved for severe atopic dermatitis. The company’s collaborative approach with AdvanCell and Chugai Pharmaceutical underscores its commitment to innovation in oncology and rare diseases. With a market capitalization exceeding $657 billion, Lilly remains a dominant player in the pharmaceutical industry, driven by its robust R&D investments and strategic partnerships.